Who are Usual dopaminergic per os treatment's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Barhemsys, Rexulti, Vraylar, Aristada, Lonasen, Nuvigil.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/usual-dopaminergic-per-os-treatment.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Usual dopaminergic per os treatment — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Usual dopaminergic per os treatment (Usual dopaminergic per os treatment) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dopamine agonist. Area: Neurology.

phase 3 Dopamine agonist Dopamine receptor Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Usual dopaminergic per os treatment (Usual dopaminergic per os treatment) — Rennes University Hospital. Activates dopaminergic receptors to increase dopamine levels in the brain.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Usual dopaminergic per os treatment TARGET	Usual dopaminergic per os treatment	Rennes University Hospital	phase 3	Dopamine agonist	Dopamine receptor
Barhemsys	AMISULPRIDE	Acacia	marketed	Dopamine-2 Receptor Antagonist [EPC]	D(2) dopamine receptor	2020-01-01
Rexulti	BREXPIPRAZOLE	Otsuka	marketed	Atypical Antipsychotic [EPC]	D(2) dopamine receptor	2015-01-01
Vraylar	CARIPRAZINE	AbbVie	marketed	Atypical Antipsychotic [EPC]	D(3) dopamine receptor	2015-01-01
Aristada	ARIPIPRAZOLE LAUROXIL	Alkermes Inc	marketed		D(2) dopamine receptor	2015-01-01
Lonasen	BLONANSERIN	Dainippon Sumitomo Pharma Co., Ltd.	marketed	blonanserin	D(2) dopamine receptor	2008-01-01
Nuvigil	ARMODAFINIL	Nuvo Pharms	marketed	armodafinil	D(2) dopamine receptor	2007-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dopamine agonist class)

Sumitomo Pharma America, Inc. · 2 drugs in this class
University Hospital, Toulouse · 2 drugs in this class
Rennes University Hospital · 2 drugs in this class
Britannia Pharmaceuticals Ltd. · 1 drug in this class
Desitin Arzneimittel GmbH · 1 drug in this class
GlaxoSmithKline · 1 drug in this class
Intec Pharma Ltd. · 1 drug in this class
Leiden University Medical Center · 1 drug in this class
Ludwig-Maximilians - University of Munich · 1 drug in this class
Massachusetts General Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Usual dopaminergic per os treatment — Competitive Intelligence Brief. https://druglandscape.com/ci/usual-dopaminergic-per-os-treatment. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab